INTRODUCTION
Colchicine is used to treat Familial Mediterranean fever (FMF) but is valuable in other inflammatory diseases such as gouty arthritis, Behçet's disease, and recurring pericarditis with effusion (Niel and Shermann, 2006; Cocco et al., 2010) . Three proteins mediate colchicine pharmacokinetics: tubulin, cytochrome P450 3A4 (CYP3A4), and P-glycoprotein (P-gp). Tubulin is a colchicine receptor that governs the plasma elimination half-life of the drug. Intestinal and hepatic CYP3A4 is fundamental in the biotransformation of colchicine. P-gp is a cell efflux pump that regulates the tissue distribution of colchicine and its excretion via the biliary tract and kidneys (Niel and Shermann, 2006) . P-gp, encoded by the multidrug resistance 1 gene (P-gp/MDR1, also known as ABCB1), is expressed in several organs, including the intestine, liver, and kidney, and mediates detoxification of numerous drugs such as colchicine (Ambudkar et al., 1999; Kimura et al., 2007) . P-gp affects the absorption, distribution, and elimination of its substrates. The P-gp/MDR1 gene is highly polymorphic, with approximately 50 single nucleotide polymorphisms (SNPs) in the coding exons (Vicente et al., 2008) . These variants alter the pharmacokinetics and pharmacodynamics of several P-gp drug substrates, accounting for differences in bioavailability in some substrate classes (Hoffmeyer et al., 2000; Kim et al., 2001; Jamroziak et al., 2004; Vicente et al., 2008) . Altered P-gp/MDR1 activity due to induction and/or inhibition can cause drugdrug interactions with altered drug pharmacokinetics and response (Zhou, 2008) . When inhibitors or modulators are prescribed in combination, changes in P-gp activity may lead to intracellular accumulation of colchicine and increased pharmacological or toxic effects. These sites are also key colchicine targets that may explain the wide inter-individual variations in responses to the drug (Niel and Shermann, 2006) .
The main route of colchicine elimination is via hepatobiliary excretion (Ferron et al., 1996; Tateishi et al., 1997; Dvorak et al., 2003) and with the feces (Tateishi et al., 1997; Dvorak et al., 2003) . Kidneys contribute to <20% of clearance (Lange et al., 2001; Molad, 2002; Niel and Shermann, 2006) . The steroid hydroxylase CYP3A4 is the most abundant P-450 enzyme in the human liver, metabolizing more than 50% of prescription drugs. Cytochrome P-450 genes constitute a superfamily encoding different isoenzymes that account for phase I drug metabolism. In humans, more than 40 cytochrome P-450s have been identified and sequenced (Hasler, 1999; Nebert and Russell, 2002) . CYP3A4 is abundantly and constitutively expressed in hepatic and intestinal epithelia (Hesselink et al., 2003) , so the reported increase in transcriptional activity shown by the CYP3A4*1B allele in vitro would theoretically also reflect significant enzymatic activity in vivo (Turolo et al., 2010) .
In this study, we explored the relationship between CYP3A4 and P-gp/MDR1 polymorphisms and therapeutic colchicine dose in FMF patients.
MATERIAL AND METHODS

Patient selection
The Human Research Ethics Committee of Abant Izzet Baysal University approved the study (#2009/100-39). All patients who were invited to join the study agreed to participate. All patients gave informed consent for molecular testing. A total of 48 patients aged 16 years and over (mean age 33.24 ± 12.32) and diagnosed with FMF according to Tel-Hashomer criteria (Fonnesu et al., 2009) were enrolled. Although the female-to-male ratio was 1.28 (27/21), there was a significant difference between females and males (P = 0.02). Mean age at onset of symptoms was 16.5 ± 11 (14.5 ± 9.34 in females and 19 ± 13.7 in males). Demographic features are presented in Table 1 .
The disease severity score of each patient was calculated according to the scoring system suggested by Pras et al. (1998) . None of the patients was using CYP3A4 and P-gp/MDR1 substrate or CYP3A4 and P-gp/MDR1 inhibiting drugs other than colchicine.
DNA extraction and MEFV gene analysis
Peripheral venous blood samples (3 mL) were collected in EDTA tubes. Genomic DNA was extracted with Blood DNA Extraction Kits (Vivantis, Malesia). The most common 5 (M694V, M680I, M694I, V726A, E148Q) mutations in exons 2 and 10 of the MEFV (Mediterranean fever) gene were determined by real-time PCR on a Rotor Gene 6000 LightCycler (Corbett Life Science, Concord, NSW, Australia) according to manufacturer protocols (Dr. Zeydanli, Turkey).
P-gp/MDR1 and CYP3A4 polymorphisms
In our study group, the T-129C polymorphism of the P-gp/MDR1 gene was non-informative. 3435C>T, (-)1A>G, 61A>G, 1199G>A, 1236C>T, 2677G>A, and 2677G>T in P-gp/ MDR1 and 3435C>T, *1B (-392A>G), *2 (15713T>C), *3 (23171T>C), *12(21896C>T), and *17(15615T>C) in CYP3A4 were analyzed as described by the manufacturer on a fullyautomated microarray-based analyzer (INFINITI TM , AutoGenomics, Inc., Vista, CA, USA).
Statistical analyses
SPSS (Statistical Package for Social Sciences) for Windows v16.0 was used for data analysis. Continuous variables are reported as means ± standard deviation. Continuous and categorical variables were compared by the Student t-test and chi-square tests, respectively. Comparisons of parametric variables were carried out by ANOVA with Tukey's post hoc testing while those of non-parametric variables and percentages were performed by KruskalWallis and chi-square tests. P < 0.05 was considered to be significant in all tests.
RESULTS
Among the clinical findings of the disease, presence of erythema differed significantly between males and females (P = 0.02), while none of the other symptoms statistically differed between genders (P > 0.05) ( Table 1) . Table 2 shows the distribution of MEFV gene mutations with respect to gender and colchicine dose. When we compared the treatment doses of colchicine and distributions of MEFV gene mutations, we found statistically significant correlation (P > 0.05). We did not find a statistically significant correlation. Tables 3 and 4 show distributions of genotypes related to P-gp/ MDR1 and CYP3A4 polymorphisms by gender. There was no significant difference between females and males in terms of the distribution of P-gp/MDR1 polymorphisms (P > 0.05). There was also no difference in mean colchicine dose between genotypic variants (P > 0.05).
There were significant differences in the genotypic distributions of 15713T>C and 15615T>C between females and males (P = 0.03 and P = 0.01, respectively). However, the relationship between colchicine dose and CYP3A4 polymorphism was not significant (P > 0.05). Table 3 . Distribution of the P-gp/MDR1 genotype with regard to gender and daily colchicine dosing interval.
*Colchicine 0.5 mg tablets were used. Table 4 . Distribution of the CYP3A4 genotype with regard to gender and colchicine dose.
*Colchicine 0.5 mg tablets were used; a some of the patients could not be analyzed due to technical reasons; b statistically significant (P < 0.05).
DISCUSSION
The localization of P-gp/MDR1 and CYP3A indicates that the some of the substrates metabolized by CYP3A may be controlled by P-gp/MDR1. P-gp/MDR1 also mediates the counteracting active transport of drugs back to the lumen after passive absorption into the enterocytes (Cummins et al., 2002) . The drug is continuously circulated between the lumen and enterocytes, allowing CYP3A constant access to the drug molecule. This eventually leads to lower drug saturation and non-absorption. Therefore, circulation of the counter transportation of P-gp/MDR1 and metabolism mediated by CYP3A in the intestine reduces oral bioavailability of a drug by controlling the concentration of molecules entering the systemic circulation (Zhou, 2008) . Wide inter-individual variations in the expression and activity of CYP3A have been demonstrated in the human liver (Shimada et al., 1994; Westlind et al., 1999) . The CYP3A cluster consists of at least 2 members: CYP3A4 and CYP3A5, with polypeptides 4 and 5, respectively, in its protein structure. About 90% of the inter-individual variability of CYP3A4 activity is caused by genetic factors (Ozdemir et al., 2000; Evans and McLeod 2003) . CYP3A4 plays a key role in metabolizing colchicine by demethylating the 3 methoxy groups in the molecule. CYP3A4 activity varies across individuals. The result is decreased colchicine clearance from the body, which affects treatment response (Niel and Shermann, 2006) . There is a broad range of overlapping substrate specificities and tissue distribution for CYP3A and P-gp/MDR1 for what are known as CYP/P-gp substrates. P-gp/MDR1 and CYP3A act synergistically as a protective barrier in the bioavailability of orally administered colchicine (Cummins et al., 2002; Niel and Shermann, 2006) . To date, more than 40 SNPs in CYP3A4 and more than 50 SNPs in P-gp/MDR1 have been identified (Hoffmeyer et al., 2000; Brinkmann and Eichelbaum, 2001; Marzolini et al., 2004; Du et al., 2006) . Among them, the most frequently studied SNPs are the G2677T/A transversion (A893S) in exon 21 and the synonymous C3435T transition in exon 26. P-gp/MDR1 SNPs C3435T and G2677T/A affect expression of P-gp and CYP3A4 (Goto et al., 2002; Lamba et al., 2006) . Some FMF patients fail to achieve sufficient response or achieve no response at all despite high doses of colchicine. The threshold between therapeutic and toxic doses of colchicine is narrow and absorption, distribution, and excretion of the drug show significant inter-individual variability (Terkeltaub, 2009) . Therefore, we investigated the relationships between polymorphisms in P-gp/MDR1 and CYP3A4 and treatment dose of colchicine in FMF patients with the aim of establishing the optimal dose of colchicine and reducing adverse effects to a minimum. To serve this purpose, we analyzed 48 patients using colchicine for FMF for presence of CYP3A4 [3435C>T, *1B (-392A>G), *2 (15713T>C), *3 (23171T>C), *12(21896C>T), *17(15615T>C)] and P-gp/MDR1 [3435C>T, (-)1A>G, 61A>G, 1199G>A, 1236C>T, 2677G>A, 2677G>T)] polymorphisms. Treatment doses of colchicine among our patients did not differ between genotypic variants of P-gp/MDR1 and CYP3A4. Significant gender differences were observed in 15713T>C and 15615T>C polymorphisms of CYP3A4 (P = 0.03 and P = 0.01, respectively) but not in P-gp/MDR1. A study on the Turkish population by Tufan et al. (2007) showed that C3435T of P-gp/MDR1 was related to colchicine response in FMF patients and patients with the TT genotype responded better to treatment. However, this contradicts our finding of no significant relationship between clinical response achieved by colchicine treatment dose and CYP3A4 and P-gp/MDR1 polymorphisms. On the other hand, it is difficult to fully understand the individual roles of CYP3A4 and P-gp/MDR1 in colchicine bioavailability and we believe that different epigenetic mechanisms might also be in play. Hosohata et al. (2009) showed that P-gp/MDR1 G2677T/A-C3435T haplotypes significantly influenced intestinal expression in women. Their results suggest that the P-gp/ MDR1 haplotype would contribute to the inter-individual variability of intestinal expression of CYP3A4 and CYP3A4-mediated drug interactions. Our results revealed no significant gender difference in P-gp/MDR1 polymorphisms. However, 15713T>C and 15615T>C polymorphisms of CYP3A4 were more frequent in males. Therefore, biotransformation of colchicine in males may differ from that in females.
In conclusion, to the best of our knowledge, this is the first study to collectively evaluate polymorphisms of both P-gp/MDR1 [3435C>T, (-)1A>G, 61A>G, 1199G>A, 1236C>T, 2677G>A, 2677G>T)] and CYP3A4 [3435C>T, *1B (-392A>G), *2 (15713T>C), *3 (23171T>C), *12(21896C>T), *17(15615T>C)] in patients with FMF. The study has addressed the frequency of CYP3A4 polymorphisms in FMF, and the results indicate that CYP3A4 15713T>C and 15615T>C polymorphisms may be associated with male FMF in the Turkish population. However, P-gp/MDR1 and CYP3A4 polymorphisms may not be related to colchicine treatment. These might reflect disparities in different frequencies of P-gp/ MDR1 and CYP3A4 polymorphisms in different ethnicities or other genetic factors might be implicated. It would be useful to carry out large population-based epidemiologic studies of P-gp/MDR1 and CYP3A4 genotypes.
